Cancer - New-wiki

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel Novel	Symbols ERBB4 and TFAP2C	Name 1 erb-b2 receptor tyrosine kinase 4	Name2 transcription factor AP-2 gamma	Pathway 1	Pathway 2 SUMOylation of transcription factors Negative regulation of activity of TFAP2 (AP-2) family transcription factors Negative regulation of activity of TFAP2 (AP-2) family transcription factors TFAP2 (AP-2) family regulates transcription of other transcription factors Activation of the TFAP2 (AP-2) family of transcription factors TFAP2 (AP-2) family regulates transcription of growth factors and their receptors TFAP2 (AP-2) family regulates transcription of cell cycle factors Specification of primordial germ cells Specification of the neural plate border Specification of the neural plate border Developmental Lineage of Mammary Stem Cells	Drugs 1 Afatinib Fostamatinib Brigatinib Zanubrutinib	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols ERBB4 and NRG4	Name 1 erb-b2 receptor tyrosine kinase 4	Name2 neuregulin 4	Pathway 1	Pathway 2 Signaling by ERBB2 Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PI3K events in ERBB4 signaling SHC1 events in ERBB4 signaling Nuclear signaling by ERBB4 PIP3 activates AKT signaling GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 TMD/JMD mutants	Drugs 1 Afatinib Fostamatinib Brigatinib Zanubrutinib	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols ERBB4 and NRG3	Name 1 erb-b2 receptor tyrosine kinase 4	Name2 neuregulin 3	Pathway 1	Pathway 2 Signaling by ERBB2 Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PI3K events in ERBB4 signaling SHC1 events in ERBB4 signaling Nuclear signaling by ERBB4 PIP3 activates AKT signaling GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 TMD/JMD mutants	Drugs 1 Afatinib Fostamatinib Brigatinib Zanubrutinib	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols BCL2L1 and PINK1	Name 1 BCL2 like 1	Name2 PTEN induced kinase 1	Pathway 1 BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members Interleukin-4 and Interleukin-13 signaling The NLRP1 inflammasome RAS processing SARS-CoV-1-mediated effects on programmed cell death STAT5 activation downstream of FLT3 ITD mutants NFE2L2 regulating tumorigenic genes	Pathway 2 PINK1-PRKN Mediated Mitophagy FOXO-mediated transcription of cell death genes	Drugs 1 4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID Gossypol	Drugs 2	Diseases 1	Diseases 2 Parkinson's disease (PD)
Novel Novel	Symbols BCL2L1 and GSK3A	Name 1 BCL2 like 1	Name2 glycogen synthase kinase 3 alpha	Pathway 1 BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members Interleukin-4 and Interleukin-13 signaling The NLRP1 inflammasome RAS processing SARS-CoV-1-mediated effects on programmed cell death STAT5 activation downstream of FLT3 ITD mutants NFE2L2 regulating tumorigenic genes	Pathway 2 AKT phosphorylates targets in the cytosol XBP1(S) activates chaperone genes Constitutive Signaling by AKT1 E17K in Cancer Suppression of apoptosis Maturation of nucleoprotein Maturation of nucleoprotein	Drugs 1 4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID Gossypol	Drugs 2 Fostamatinib	Diseases 1	Diseases 2
Novel Novel	Symbols BAX and BCL2A1	Name 1 BCL2 associated X, apoptosis regulator	Name2 BCL2 related protein A1	Pathway 1 Release of apoptotic factors from the mitochondria Activation, translocation and oligomerization of BAX Pyroptosis TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest Transcriptional regulation by RUNX2 NTRK3 as a dependence receptor	Pathway 2 Nuclear events stimulated by ALK signaling in cancer Regulation of MITF-M-dependent genes involved in apoptosis	Drugs 1 TAK-901	Drugs 2	Diseases 1 Colorectal cancer	Diseases 2
Novel Novel	Symbols ABCA1 and FADD	Name 1 ATP binding cassette subfamily A member 1	Name2 Fas associated via death domain	Pathway 1 PPARA activates gene expression Defective ABCA1 causes TGD HDL assembly NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux	Pathway 2 Caspase activation via Death Receptors in the presence of ligand TRIF-mediated programmed cell death Regulation by c-FLIP RIPK1-mediated regulated necrosis CASP8 activity is inhibited TNFR1-induced proapoptotic signaling Regulation of TNFR1 signaling Regulation of necroptotic cell death Dimerization of procaspase-8 FasL/ CD95L signaling TRAIL signaling TLR3-mediated TICAM1-dependent programmed cell death NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 Defective RIPK1-mediated regulated necrosis	Drugs 1 ATP Glyburide Probucol	Drugs 2	Diseases 1 Tangier disease Hypoalphalipoproteinemia	Diseases 2
Novel Novel	Symbols LRP2 and ANAPC10	Name 1 LDL receptor related protein 2	Name2 anaphase promoting complex subunit 10	Pathway 1 Vitamin D (calciferol) metabolism Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis Retinoid metabolism and transport Transport of RCbl within the body	Pathway 2 Inactivation of APC/C via direct inhibition of the APC/C complex APC/C:Cdc20 mediated degradation of Cyclin B Autodegradation of Cdh1 by Cdh1:APC/C APC/C:Cdc20 mediated degradation of Securin APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Cdc20:Phospho-APC/C mediated degradation of Cyclin A Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase Regulation of APC/C activators between G1/S and early anaphase APC/C:Cdc20 mediated degradation of mitotic proteins Phosphorylation of the APC/C APC-Cdc20 mediated degradation of Nek2A Separation of Sister Chromatids Senescence-Associated Secretory Phenotype (SASP) Assembly of the pre-replicative complex CDK-mediated phosphorylation and removal of Cdc6 Transcriptional Regulation by VENTX Aberrant regulation of mitotic exit in cancer due to RB1 defects Antigen processing: Ubiquitination & Proteasome degradation	Drugs 1 Urokinase Insulin human	Drugs 2	Diseases 1 Donnai-Barrow syndrome; Faciooculoacousticorenal syndrome	Diseases 2
Novel Novel	Symbols DAB2 and CDC16	Name 1 DAB adaptor protein 2	Name2 cell division cycle 16	Pathway 1 Gap junction degradation Formation of annular gap junctions Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis	Pathway 2 Inactivation of APC/C via direct inhibition of the APC/C complex APC/C:Cdc20 mediated degradation of Cyclin B Autodegradation of Cdh1 by Cdh1:APC/C APC/C:Cdc20 mediated degradation of Securin APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Cdc20:Phospho-APC/C mediated degradation of Cyclin A Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase Regulation of APC/C activators between G1/S and early anaphase APC/C:Cdc20 mediated degradation of mitotic proteins Phosphorylation of the APC/C APC-Cdc20 mediated degradation of Nek2A Separation of Sister Chromatids Senescence-Associated Secretory Phenotype (SASP) Assembly of the pre-replicative complex CDK-mediated phosphorylation and removal of Cdc6 Transcriptional Regulation by VENTX Aberrant regulation of mitotic exit in cancer due to RB1 defects Antigen processing: Ubiquitination & Proteasome degradation	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols DLG2 and GRID1	Name 1 discs large MAGUK scaffold protein 2	Name2 glutamate ionotropic receptor delta type subunit 1	Pathway 1 Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor RAF/MAP kinase cascade Neurexins and neuroligins Neurexins and neuroligins Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols PTPN12 and LMTK2	Name 1 protein tyrosine phosphatase non-receptor type 12	Name2 lemur tyrosine kinase 2	Pathway 1 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling EGFR downregulation Signaling by PDGF Downregulation of ERBB2 signaling Interleukin-37 signaling Constitutive Signaling by Overexpressed ERBB2	Pathway 2	Drugs 1 Tiludronic acid	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols PDE4D and AKAP6	Name 1 phosphodiesterase 4D	Name2 A-kinase anchoring protein 6	Pathway 1 DARPP-32 events G alpha (s) signalling events	Pathway 2	Drugs 1 Adenosine phosphate Caffeine Caffeine Dyphylline Iloprost Papaverine Amrinone Roflumilast Piclamilast Rolipram Rolipram 3,5-Dimethyl-1-(3-Nitrophenyl)-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester 2-[3-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Propylamino]-2-Hydroxymethyl-Propane-1,3-Diol Zardaverine 1-(4-Aminophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester (S)-Rolipram Cilomilast (R)-Rolipram 3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester 1-(4-Methoxyphenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester Crisaborole Ibudilast Tetomilast Exisulind (4R)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one 3,5-DIMETHYL-1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER 3-isobutyl-1-methyl-7H-xanthine 4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid Trapidil	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols AP1B1 and AP1G1	Name 1 adaptor related protein complex 1 subunit beta 1	Name2 adaptor related protein complex 1 subunit gamma 1	Pathway 1 Nef mediated downregulation of MHC class I complex cell surface expression MHC class II antigen presentation Lysosome Vesicle Biogenesis Golgi Associated Vesicle Biogenesis	Pathway 2 Nef mediated downregulation of MHC class I complex cell surface expression MHC class II antigen presentation Lysosome Vesicle Biogenesis Golgi Associated Vesicle Biogenesis	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols AP1B1 and AGR3	Name 1 adaptor related protein complex 1 subunit beta 1	Name2 anterior gradient 3, protein disulphide isomerase family member	Pathway 1 Nef mediated downregulation of MHC class I complex cell surface expression MHC class II antigen presentation Lysosome Vesicle Biogenesis Golgi Associated Vesicle Biogenesis	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols CDKN2A and HLA-DOB	Name 1 cyclin dependent kinase inhibitor 2A	Name2 major histocompatibility complex, class II, DO beta	Pathway 1 Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Cyclin D associated events in G1 Transcriptional Regulation by VENTX Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Regulation of MITF-M-dependent genes involved in cell cycle and proliferation Apoptotic factor-mediated response Oxidative Stress Induced Senescence Oncogene Induced Senescence SUMOylation of DNA damage response and repair proteins SUMOylation of transcription factors Regulation of TP53 Degradation Stabilization of p53 Regulation of RUNX3 expression and activity Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function Evasion of Oncogene Induced Senescence Due to p14ARF Defects Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects Nuclear events mediated by NFE2L2	Pathway 2 MHC class II antigen presentation	Drugs 1	Drugs 2	Diseases 1 Chronic myeloid leukemia (CML) Non-small cell lung cancer Malignant islet cell carcinoma Adult T-cell leukemia Esophageal cancer Glioma Pancreatic cancer Nasopharyngeal cancer Hepatocellular carcinoma Squamous cell carcinoma Penile cancer Oral cancer Malignant melanoma Burkitt lymphoma Gallbladder cancer Bladder cancer Laryngeal cancer Cholangiocarcinoma Malignant pleural mesothelioma Osteosarcoma Type II diabetes mellitus	Diseases 2
Novel Novel	Symbols TLE5 and SIX3	Name 1 TLE family member 5, transcriptional modulator	Name2 SIX homeobox 3	Pathway 1 Repression of WNT target genes	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols TLE5 and SIX1	Name 1 TLE family member 5, transcriptional modulator	Name2 SIX homeobox 1	Pathway 1 Repression of WNT target genes	Pathway 2 Formation of the ureteric bud	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Contiguous gene deletion syndrome involving EYA1, including: Oto-facio-cervical syndrome (OFC); Branchiootic syndrome 1 (BOS1); Branchio-oto-renal syndrome (BOR)
Novel Novel	Symbols TLE5 and TFAP2D	Name 1 TLE family member 5, transcriptional modulator	Name2 transcription factor AP-2 delta	Pathway 1 Repression of WNT target genes	Pathway 2 Negative regulation of activity of TFAP2 (AP-2) family transcription factors Negative regulation of activity of TFAP2 (AP-2) family transcription factors Activation of the TFAP2 (AP-2) family of transcription factors	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols TLE5 and UBAP2	Name 1 TLE family member 5, transcriptional modulator	Name2 ubiquitin associated protein 2	Pathway 1 Repression of WNT target genes	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols TLE5 and CT55	Name 1 TLE family member 5, transcriptional modulator	Name2 cancer/testis antigen 55	Pathway 1 Repression of WNT target genes	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols ERBB4 and TFAP2C	Name 1 erb-b2 receptor tyrosine kinase 4	Name2 transcription factor AP-2 gamma	Pathway 1	Pathway 2 SUMOylation of transcription factors Negative regulation of activity of TFAP2 (AP-2) family transcription factors Negative regulation of activity of TFAP2 (AP-2) family transcription factors TFAP2 (AP-2) family regulates transcription of other transcription factors Activation of the TFAP2 (AP-2) family of transcription factors TFAP2 (AP-2) family regulates transcription of growth factors and their receptors TFAP2 (AP-2) family regulates transcription of cell cycle factors Specification of primordial germ cells Specification of the neural plate border Specification of the neural plate border Developmental Lineage of Mammary Stem Cells	Drugs 1 Afatinib Fostamatinib Brigatinib Zanubrutinib	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols ERBB4 and NRG4	Name 1 erb-b2 receptor tyrosine kinase 4	Name2 neuregulin 4	Pathway 1	Pathway 2 Signaling by ERBB2 Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PI3K events in ERBB4 signaling SHC1 events in ERBB4 signaling Nuclear signaling by ERBB4 PIP3 activates AKT signaling GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 TMD/JMD mutants	Drugs 1 Afatinib Fostamatinib Brigatinib Zanubrutinib	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols ERBB4 and NRG3	Name 1 erb-b2 receptor tyrosine kinase 4	Name2 neuregulin 3	Pathway 1	Pathway 2 Signaling by ERBB2 Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PI3K events in ERBB4 signaling SHC1 events in ERBB4 signaling Nuclear signaling by ERBB4 PIP3 activates AKT signaling GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 TMD/JMD mutants	Drugs 1 Afatinib Fostamatinib Brigatinib Zanubrutinib	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols BCL2L1 and PINK1	Name 1 BCL2 like 1	Name2 PTEN induced kinase 1	Pathway 1 BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members Interleukin-4 and Interleukin-13 signaling The NLRP1 inflammasome RAS processing SARS-CoV-1-mediated effects on programmed cell death STAT5 activation downstream of FLT3 ITD mutants NFE2L2 regulating tumorigenic genes	Pathway 2 PINK1-PRKN Mediated Mitophagy FOXO-mediated transcription of cell death genes	Drugs 1 4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID Gossypol	Drugs 2	Diseases 1	Diseases 2 Parkinson's disease (PD)
Novel	Symbols BCL2L1 and GSK3A	Name 1 BCL2 like 1	Name2 glycogen synthase kinase 3 alpha	Pathway 1 BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members Interleukin-4 and Interleukin-13 signaling The NLRP1 inflammasome RAS processing SARS-CoV-1-mediated effects on programmed cell death STAT5 activation downstream of FLT3 ITD mutants NFE2L2 regulating tumorigenic genes	Pathway 2 AKT phosphorylates targets in the cytosol XBP1(S) activates chaperone genes Constitutive Signaling by AKT1 E17K in Cancer Suppression of apoptosis Maturation of nucleoprotein Maturation of nucleoprotein	Drugs 1 4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID Gossypol	Drugs 2 Fostamatinib	Diseases 1	Diseases 2
Novel	Symbols BAX and BCL2A1	Name 1 BCL2 associated X, apoptosis regulator	Name2 BCL2 related protein A1	Pathway 1 Release of apoptotic factors from the mitochondria Activation, translocation and oligomerization of BAX Pyroptosis TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest Transcriptional regulation by RUNX2 NTRK3 as a dependence receptor	Pathway 2 Nuclear events stimulated by ALK signaling in cancer Regulation of MITF-M-dependent genes involved in apoptosis	Drugs 1 TAK-901	Drugs 2	Diseases 1 Colorectal cancer	Diseases 2
Novel	Symbols ABCA1 and FADD	Name 1 ATP binding cassette subfamily A member 1	Name2 Fas associated via death domain	Pathway 1 PPARA activates gene expression Defective ABCA1 causes TGD HDL assembly NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux	Pathway 2 Caspase activation via Death Receptors in the presence of ligand TRIF-mediated programmed cell death Regulation by c-FLIP RIPK1-mediated regulated necrosis CASP8 activity is inhibited TNFR1-induced proapoptotic signaling Regulation of TNFR1 signaling Regulation of necroptotic cell death Dimerization of procaspase-8 FasL/ CD95L signaling TRAIL signaling TLR3-mediated TICAM1-dependent programmed cell death NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 Defective RIPK1-mediated regulated necrosis	Drugs 1 ATP Glyburide Probucol	Drugs 2	Diseases 1 Tangier disease Hypoalphalipoproteinemia	Diseases 2
Novel	Symbols LRP2 and ANAPC10	Name 1 LDL receptor related protein 2	Name2 anaphase promoting complex subunit 10	Pathway 1 Vitamin D (calciferol) metabolism Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis Retinoid metabolism and transport Transport of RCbl within the body	Pathway 2 Inactivation of APC/C via direct inhibition of the APC/C complex APC/C:Cdc20 mediated degradation of Cyclin B Autodegradation of Cdh1 by Cdh1:APC/C APC/C:Cdc20 mediated degradation of Securin APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Cdc20:Phospho-APC/C mediated degradation of Cyclin A Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase Regulation of APC/C activators between G1/S and early anaphase APC/C:Cdc20 mediated degradation of mitotic proteins Phosphorylation of the APC/C APC-Cdc20 mediated degradation of Nek2A Separation of Sister Chromatids Senescence-Associated Secretory Phenotype (SASP) Assembly of the pre-replicative complex CDK-mediated phosphorylation and removal of Cdc6 Transcriptional Regulation by VENTX Aberrant regulation of mitotic exit in cancer due to RB1 defects Antigen processing: Ubiquitination & Proteasome degradation	Drugs 1 Urokinase Insulin human	Drugs 2	Diseases 1 Donnai-Barrow syndrome; Faciooculoacousticorenal syndrome	Diseases 2
Novel	Symbols DAB2 and CDC16	Name 1 DAB adaptor protein 2	Name2 cell division cycle 16	Pathway 1 Gap junction degradation Formation of annular gap junctions Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis	Pathway 2 Inactivation of APC/C via direct inhibition of the APC/C complex APC/C:Cdc20 mediated degradation of Cyclin B Autodegradation of Cdh1 by Cdh1:APC/C APC/C:Cdc20 mediated degradation of Securin APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Cdc20:Phospho-APC/C mediated degradation of Cyclin A Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase Regulation of APC/C activators between G1/S and early anaphase APC/C:Cdc20 mediated degradation of mitotic proteins Phosphorylation of the APC/C APC-Cdc20 mediated degradation of Nek2A Separation of Sister Chromatids Senescence-Associated Secretory Phenotype (SASP) Assembly of the pre-replicative complex CDK-mediated phosphorylation and removal of Cdc6 Transcriptional Regulation by VENTX Aberrant regulation of mitotic exit in cancer due to RB1 defects Antigen processing: Ubiquitination & Proteasome degradation	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols DLG2 and GRID1	Name 1 discs large MAGUK scaffold protein 2	Name2 glutamate ionotropic receptor delta type subunit 1	Pathway 1 Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor RAF/MAP kinase cascade Neurexins and neuroligins Neurexins and neuroligins Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols PTPN12 and LMTK2	Name 1 protein tyrosine phosphatase non-receptor type 12	Name2 lemur tyrosine kinase 2	Pathway 1 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling EGFR downregulation Signaling by PDGF Downregulation of ERBB2 signaling Interleukin-37 signaling Constitutive Signaling by Overexpressed ERBB2	Pathway 2	Drugs 1 Tiludronic acid	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols PDE4D and AKAP6	Name 1 phosphodiesterase 4D	Name2 A-kinase anchoring protein 6	Pathway 1 DARPP-32 events G alpha (s) signalling events	Pathway 2	Drugs 1 Adenosine phosphate Caffeine Caffeine Dyphylline Iloprost Papaverine Amrinone Roflumilast Piclamilast Rolipram Rolipram 3,5-Dimethyl-1-(3-Nitrophenyl)-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester 2-[3-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Propylamino]-2-Hydroxymethyl-Propane-1,3-Diol Zardaverine 1-(4-Aminophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester (S)-Rolipram Cilomilast (R)-Rolipram 3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester 1-(4-Methoxyphenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester Crisaborole Ibudilast Tetomilast Exisulind (4R)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one 3,5-DIMETHYL-1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER 3-isobutyl-1-methyl-7H-xanthine 4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid Trapidil	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols AP1B1 and AP1G1	Name 1 adaptor related protein complex 1 subunit beta 1	Name2 adaptor related protein complex 1 subunit gamma 1	Pathway 1 Nef mediated downregulation of MHC class I complex cell surface expression MHC class II antigen presentation Lysosome Vesicle Biogenesis Golgi Associated Vesicle Biogenesis	Pathway 2 Nef mediated downregulation of MHC class I complex cell surface expression MHC class II antigen presentation Lysosome Vesicle Biogenesis Golgi Associated Vesicle Biogenesis	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols AP1B1 and AGR3	Name 1 adaptor related protein complex 1 subunit beta 1	Name2 anterior gradient 3, protein disulphide isomerase family member	Pathway 1 Nef mediated downregulation of MHC class I complex cell surface expression MHC class II antigen presentation Lysosome Vesicle Biogenesis Golgi Associated Vesicle Biogenesis	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols CDKN2A and HLA-DOB	Name 1 cyclin dependent kinase inhibitor 2A	Name2 major histocompatibility complex, class II, DO beta	Pathway 1 Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Cyclin D associated events in G1 Transcriptional Regulation by VENTX Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Regulation of MITF-M-dependent genes involved in cell cycle and proliferation Apoptotic factor-mediated response Oxidative Stress Induced Senescence Oncogene Induced Senescence SUMOylation of DNA damage response and repair proteins SUMOylation of transcription factors Regulation of TP53 Degradation Stabilization of p53 Regulation of RUNX3 expression and activity Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function Evasion of Oncogene Induced Senescence Due to p14ARF Defects Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects Nuclear events mediated by NFE2L2	Pathway 2 MHC class II antigen presentation	Drugs 1	Drugs 2	Diseases 1 Chronic myeloid leukemia (CML) Non-small cell lung cancer Malignant islet cell carcinoma Adult T-cell leukemia Esophageal cancer Glioma Pancreatic cancer Nasopharyngeal cancer Hepatocellular carcinoma Squamous cell carcinoma Penile cancer Oral cancer Malignant melanoma Burkitt lymphoma Gallbladder cancer Bladder cancer Laryngeal cancer Cholangiocarcinoma Malignant pleural mesothelioma Osteosarcoma Type II diabetes mellitus	Diseases 2
Novel	Symbols TLE5 and SIX3	Name 1 TLE family member 5, transcriptional modulator	Name2 SIX homeobox 3	Pathway 1 Repression of WNT target genes	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols TLE5 and SIX1	Name 1 TLE family member 5, transcriptional modulator	Name2 SIX homeobox 1	Pathway 1 Repression of WNT target genes	Pathway 2 Formation of the ureteric bud	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Contiguous gene deletion syndrome involving EYA1, including: Oto-facio-cervical syndrome (OFC); Branchiootic syndrome 1 (BOS1); Branchio-oto-renal syndrome (BOR)
Novel	Symbols TLE5 and TFAP2D	Name 1 TLE family member 5, transcriptional modulator	Name2 transcription factor AP-2 delta	Pathway 1 Repression of WNT target genes	Pathway 2 Negative regulation of activity of TFAP2 (AP-2) family transcription factors Negative regulation of activity of TFAP2 (AP-2) family transcription factors Activation of the TFAP2 (AP-2) family of transcription factors	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols TLE5 and UBAP2	Name 1 TLE family member 5, transcriptional modulator	Name2 ubiquitin associated protein 2	Pathway 1 Repression of WNT target genes	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols TLE5 and CT55	Name 1 TLE family member 5, transcriptional modulator	Name2 cancer/testis antigen 55	Pathway 1 Repression of WNT target genes	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2

Page 49 out of 98 pages

Search Results : Cancer